SINGAPORE - Media OutReach Newswire - 22 December 2023 - Novo Nordisk Pharma (Thailand) Ltd. has emerged triumphant by securing three prestigious accolades at the Asia Pacific Enterprise Awards (APEA) ...

Eli Lilly and Novo Nordisk didn't quite beat expectations with their recent earnings. Their weight loss drugs slightly underperformed. That underperformance may portend more difficulty.

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

After massive market cap growth for Eli Lilly and Novo Nordisk since the start of the decade, investor enthusiasm dimmed for the two most valuable companies in the industry in the third quarter.

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

1 Day NVO 1.88% DJIA 0.68% S&P 500 -0.03% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

For mixed-use development revenue, the company saw $17 million in the third quarter of 2024, up from $16 million in the prior year period, primarily due to increases in parking and rental income.